title: Early Avastin management in acute retinal vein occlusion.
abstract: OBJECTIVE
  To evaluate the safety, functional and anatomical effects of intravitreal Avastin (bevacizumab) in treatment of recent retinal venous occlusion.
  
  
  METHODS
  Prospective interventional series non-comparative study.
  
  
  METHODS
  Department of Ophthalmology, Faculty of Medicine, El-Minia University, Egypt.
  
  
  METHODS
  The study included 30 eyes of 30 patients with recent retinal venous occlusion of less than 3 months duration 12 eyes (40%) of patients with central retinal vein occlusion (CRVO) and 18 eyes (60%) with branch retinal vein occlusion (BRVO) were injected with intravitreal bevacizumab 1.25 mg (0.05 ml) of commercially available bevacizumab [Avastin; Genentech, Inc., San Francisco, CA] at a concentration of 25 mg/ml as a primary treatment. The mean number of injections was 2.7 (range, 1-6 injections) 6-8 weeks intervals and follow-up for 12 months (range, 9-13 months). Patients underwent visual acuity testing (VA) as functional assessment. Anatomically, optical coherence tomography (OCT) is used for measurement of central retinal thickness (CRT) to detect macular edema (ME), fundus photography and fluorescein angiography (FA) to detect venous tortuosity, optic disc edema and surface wrinkling rather than ME. All finding at baseline and each follow-up visit were reported.
  
  
  RESULTS
  The mean age of all patients was 65.3 years ± 8.5 (range, 55-82 years), 20 males and 10 females patients. The mean baseline VA was 20/240 (log MAR 1.08 ± 0.52) and improved to 20/60 (log MAR 0.48 ± 0.32) with statistically significance difference change (P < 0.001). The mean baseline CRT was 455 μm ± 126 (range, 386-510), decreased to 356 μm ± 118 (range, 296-416) after 1 month with statistically significance difference change (P < 0.02) and to 402 μm ± 170 (range, 338-468) after 6 months (P < 0.067) and to 250 μm ± 48 (range, 200-298) at last follow-up with statistically significance difference change from the baseline (P < 0.001). There were great proportional decrease in venous tortuosity, optic disc edema and surface wrinkling after 1 month of injection. Neither systemic nor intraocular adverse events were reported.
  
  
  CONCLUSIONS
  Intravitreal Avastin (IVA) is safe well tolerated, effectively improve VA, fundus picture and stabilize anterior segment neo-vascular activity in patients with recent retinal venous occlusion.
authors: Department of Ophthalmology, El-Minia Faculty of Medicine, El-Minia University Hospitals, El-Minia University, Egypt.
authors: Shaaban A
authors: SA
authors: Mehany
authors: Khaled M
authors: KM
authors: Mourad
authors: Ahmad M
authors: AM
authors: Shawkat
authors: Mohammed F
authors: MF
authors: Sayed
keywords: Avastin (bevacizumab) CRVO; BRVO; FA and OCT; Intravitreal injection; Retinal venous occlusion
references: Ophthalmology. 1998 Mar;105(3):412-6
references: 9499769
references: Am J Ophthalmol. 1984 Sep 15;98(3):271-82
references: 6383055
references: Br J Ophthalmol. 2008 Apr;92(4):518-22
references: 18211942
references: Doc Ophthalmol. 2008 Mar;116(2):147-52
references: 18189152
references: Arch Ophthalmol. 1997 Apr;115(4):486-91
references: 9109757
references: Br J Ophthalmol. 2009 Apr;93(4):452-6
references: 19074916
references: Retina. 2006 Mar;26(3):279-84
references: 16508427
references: Doc Ophthalmol. 1999;97(3-4):427-31
references: 10896360
references: Am J Ophthalmol. 2007 Dec;144(6):864-71
references: 17916320
references: Histol Histopathol. 1997 Jan;12(1):99-109
references: 9046048
references: Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):309-15
references: 16133018
references: Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):27-33
references: 18696094
references: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9
references: 16156153
references: Am J Ophthalmol. 2002 Mar;133(3):373-85
references: 11860975
references: Retina. 2007 Apr-May;27(4):426-31
references: 17420693
references: Retina. 2008 Feb;28(2):212-9
references: 18301025
references: Graefes Arch Clin Exp Ophthalmol. 1999 Dec;237(12):1024-7
references: 10654172
references: Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
references: 11190017
references: Acta Ophthalmol Scand. 2007 Feb;85(1):118-9
references: 17244225
references: Retina. 2007 Oct;27(8):1013-9
references: 18040237
references: Retina. 2009 Jun;29(6):757-67
references: 19289982
references: Eye (Lond). 2006 Jan;20(1):13-7
references: 15723039
references: Curr Eye Res. 2008 Feb;33(2):111-31
references: 18293182
references: Retina. 2007 Feb;27(2):141-9
references: 17290194
references: Ophthalmology. 2007 May;114(5):835-54
references: 17397923
references: Lab Invest. 1995 Jun;72(6):638-45
references: 7540233
references: Ophthalmology. 1983 May;90(5):458-74
references: 6877778
references: Am J Ophthalmol. 2005 Oct;140(4):695-702
references: 16226521
references: Retina. 2007 Apr-May;27(4):419-25
references: 17420692
references: Eye (Lond). 2005 Jan;19(1):65-71
references: 15105817
references: Retina. 2005 Oct-Nov;25(7):851-5
references: 16205563
references: Arch Ophthalmol. 2008 Apr;126(4):513-8
references: 18413521
references: Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1241-7
references: 18546006
references: Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2399-406
references: 15223823
references: Br J Ophthalmol. 2008 Mar;92(3):351-5
references: 18211925
references: Eye (Lond). 2008 Jan;22(1):42-8
references: 16826241